Madrigal Pharmaceuticals, Inc.
MDGL
$327.70
-$6.21-1.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -24.69% | -49.33% | -54.78% | -41.16% | -26.50% |
| Total Depreciation and Amortization | 107.97% | 70.23% | 42.40% | 17.98% | 12.85% |
| Total Amortization of Deferred Charges | -13.46% | 19.98% | 59.03% | 114.31% | 202.89% |
| Total Other Non-Cash Items | 59.81% | 78.28% | 86.89% | 64.94% | 57.26% |
| Change in Net Operating Assets | -2,108.33% | 952.56% | -210.48% | -135.68% | -108.71% |
| Cash from Operations | -40.51% | -42.34% | -62.10% | -50.31% | -44.19% |
| Capital Expenditure | 1.15% | -387.92% | -1,022.29% | -800.50% | -581.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 45.53% | -697.22% | -467.19% | -501.05% | -342.16% |
| Cash from Investing | 45.40% | -695.24% | -468.74% | -502.71% | -343.13% |
| Total Debt Issued | -- | -100.00% | -70.00% | -64.71% | 30.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 38.57% | 279.55% | 284.34% | 284.88% | 100.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 73.96% | 86.35% | 59.03% |
| Cash from Financing | 23.52% | 214.91% | 235.41% | 204.84% | 89.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.20% | 6,368.84% | 1,665.60% | 616.93% | -178.45% |